FCG Investment Co Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

FCG Investment Co purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,568 shares of the biotechnology company’s stock, valued at approximately $1,637,000. United Therapeutics comprises about 1.1% of FCG Investment Co’s holdings, making the stock its 29th largest holding.

Other large investors also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after purchasing an additional 22,978 shares during the last quarter. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the period. Dimensional Fund Advisors LP increased its stake in United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after acquiring an additional 22,683 shares during the period. Pacer Advisors Inc. increased its stake in United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Finally, Swedbank AB bought a new position in United Therapeutics during the 1st quarter worth $97,316,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $348.65 on Monday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $377.03. The stock has a market capitalization of $15.46 billion, a PE ratio of 16.48, a price-to-earnings-growth ratio of 1.27 and a beta of 0.57. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average price is $354.00 and its 200-day moving average price is $313.31.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.24 EPS. Equities research analysts expect that United Therapeutics Co. will post 24.72 EPS for the current year.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $324.73, for a total transaction of $1,169,028.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,214.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $833,350.26. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,812 shares of company stock valued at $35,251,926. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. Finally, UBS Group boosted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.